A. Rob P.M. Valentijn

4.2k citations

55 papers · 3.2k indexed · 1 hit paper · h-index 25

Co-authors: Sjoerd H. van der Burg Jaap Oostendorp Marij J.P. Welters Cornelis J.M. Melief Jan W. Drijfhout Gemma G. Kenter Gert Jan Fleuren Dorien M. A. Berends-van der Meer
Topics: Immunotherapy and Immune Responses (17 papers)Cervical Cancer and HPV Research (11 papers)Carbohydrate Chemistry and Synthesis (9 papers)
Cited by: Immunology Oncology Epidemiology
Journals: New England Journal of Medicine Proceedings of the National Academy of Sciences Angewandte Chemie International Edition
Partner nations: Netherlands United States Czechia

In The Last Decade

A. Rob P.M. Valentijn

55 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia

2009 803 citations Gemma G. Kenter, Marij J.P. Welters et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by A. Rob P.M. Valentijn

Since Specialization

Citations

This map shows the geographic impact of A. Rob P.M. Valentijn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Rob P.M. Valentijn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Rob P.M. Valentijn more than expected).

Fields of papers citing papers by A. Rob P.M. Valentijn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Rob P.M. Valentijn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Rob P.M. Valentijn. The network helps show where A. Rob P.M. Valentijn may publish in the future.

Co-authorship network of co-authors of A. Rob P.M. Valentijn

This figure shows the co-authorship network connecting the top 25 collaborators of A. Rob P.M. Valentijn. A scholar is included among the top collaborators of A. Rob P.M. Valentijn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Rob P.M. Valentijn. A. Rob P.M. Valentijn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	TEIPP-vaccination in checkpoint-resistant non-small cell lung cancer: a first-in-human phase I/II dose-escalation study 2025 ·Nature Communications ·(unknown),Marij J.P. Welters,(unknown),Saskia J. Santegoets,(unknown),(unknown),Nikki M. Loof,Daphne W. Dumoulin,(unknown),(unknown),A. Rob P.M. Valentijn,Danielle Cohen,Noel F.C.C. de Miranda,Egbert F. Smit,Hans Gelderblom,Thorbald van Hall,Joachim G.J.V. Aerts,Sjoerd H. van der Burg	4
2	Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions 2022 ·Journal for ImmunoTherapy of Cancer ·Frank M. Speetjens,Marij J.P. Welters,Marije Slingerland,Mariëtte I.E. van Poelgeest,Peggy J. de Vos van Steenwijk,(unknown),(unknown),Nikki M. Loof,Gijs G. Zom,A. Rob P.M. Valentijn,Willem-Jan Krebber,Nico J. Meeuwenoord,C A H Janssen,Cornelis J.M. Melief,Gijs A. van der Marel,Dmitri V. Filippov,Sjoerd H. van der Burg,Hans Gelderblom,Ferry Ossendorp	22
3	First-in-Human Assessment of cRGD-ZW800-1, a Zwitterionic, Integrin-Targeted, Near-Infrared Fluorescent Peptide in Colon Carcinoma 2020 ·Clinical Cancer Research ·Kim S. de Valk,Marion M. Deken,Henricus J.M. Handgraaf,Shadhvi S. Bhairosingh,Okker D. Bijlstra,Michiel J. van Esdonk,Anton G.T. Terwisscha van Scheltinga,A. Rob P.M. Valentijn,(unknown),(unknown),Koen Peeters,Fabian A. Holman,Denise E. Hilling,J. Sven D. Mieog,John V. Frangioni,Jacobus Burggraaf,Alexander L. Vahrmeijer	77
4	Small Molecules for Multi-Wavelength Near-Infrared Fluorescent Mapping of Regional and Sentinel Lymph Nodes in Colorectal Cancer Staging 2020 ·Frontiers in Oncology ·(unknown),Marion M. Deken,(unknown),Shadhvi S. Bhairosingh,Daniela Salvatori,Hoon Hyun,Maged Henary,Hak Soo Choi,Cornelis F.M. Sier,Peter J.K. Kuppen,Anton G.T. Terwisscha van Scheltinga,(unknown),A. Rob P.M. Valentijn,John V. Frangioni,Alexander L. Vahrmeijer	1
5	Ototopical drops containing a novel antibacterial synthetic peptide: Safety and efficacy in adults with chronic suppurative otitis media 2020 ·PLoS ONE ·(unknown),(unknown),Ronald Brand,(unknown),Ewoud J. van Hoogdalem,R. Verrijk,(unknown),Amon R. Wafelman,A. Rob P.M. Valentijn,Johan H. M. Frijns,Pieter S. Hiemstra,Jan W. Drijfhout,Peter H. Nibbering,J. J. Grote	25
6	Fluorescence-guided tumor detection with a novel anti-EpCAM targeted antibody fragment: Preclinical validation 2018 ·Surgical Oncology ·Leonora S. F. Boogerd,Martin C. Boonstra,Hendrica A.J.M. Prevoo,Henricus J.M. Handgraaf,Peter J.K. Kuppen,Cornelis J.�H. van de Velde,Alexander Fish,Robert A. Cordfunke,A. Rob P.M. Valentijn,(unknown),Glen C. MacDonald,Jeannick Cizeau,(unknown),(unknown),Jacobus Burggraaf,Cornelis F.M. Sier,Alexander L. Vahrmeijer	29
7	Potential use of lymph node-derived HPV-specific T cells for adoptive cell therapy of cervical cancer 2016 ·Cancer Immunology Immunotherapy ·Mariëtte I.E. van Poelgeest,Valeria Visconti,(unknown),Vanessa J. van Ham,Moniek Heusinkveld,Maarten L. Zandvliet,A. Rob P.M. Valentijn,Renske Goedemans,Caroline E. van der Minne,Els M.E. Verdegaal,J. Baptist Trimbos,Sjoerd H. van der Burg,Marij J.P. Welters	23
8	Near-Infrared Fluorescence Imaging of Both Colorectal Cancer and Ureters Using a Low-Dose Integrin Targeted Probe 2014 ·Annals of Surgical Oncology ·F.P.R. Verbeek,Joost R. van der Vorst,Quirijn R.J.G. Tummers,Martin C. Boonstra,Karien E. de Rooij,Clemens W.G.M. Löwik,A. Rob P.M. Valentijn,Cornelis J.�H. van de Velde,Hak Soo Choi,John V. Frangioni,Alexander L. Vahrmeijer	51
9	Enhanced Cross-Presentation and Improved CD8+ T Cell Responses after Mannosylation of Synthetic Long Peptides in Mice 2014 ·PLoS ONE ·(unknown),Christoph Kreer,(unknown),Suzanne van Duikeren,Willemien E. Benckhuijsen,Marcel Camps,A. Rob P.M. Valentijn,Ferry Ossendorp,Jan W. Drijfhout,Ramon Arens,Sven Burgdorf	24
10	Development of a Nose Cream Containing the Synthetic Antimicrobial Peptide P60.4Ac for Eradication of Methicillin-Resistant Staphylococcus aureus Carriage 2013 ·Journal of Pharmaceutical Sciences ·Anikó Göblyös,Kirsten J. M. Schimmel,A. Rob P.M. Valentijn,(unknown),Robert A. Cordfunke,(unknown),Jaap Oostendorp,Peter H. Nibbering,Jan W. Drijfhout,Pieter S. Hiemstra,Jan den Hartigh	15
11	Addition of interferon‐α to the p53‐SLP® vaccine results in increased production of interferon‐γ in vaccinated colorectal cancer patients: A phase I/II clinical trial 2012 ·International Journal of Cancer ·Eliane C.M. Zeestraten,Frank M. Speetjens,Marij J.P. Welters,Sepideh Saadatmand,Linda F. M. Stynenbosch,Rogier Jongen,Ellen Kapiteijn,Hans Gelderblom,Hans W. Nijman,A. Rob P.M. Valentijn,Jaap Oostendorp,Lorraine M. Fathers,Jan W. Drijfhout,Cornelis J.�H. van de Velde,Peter J.K. Kuppen,Sjoerd H. van der Burg,Cornelis J.M. Melief	46
12	Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasiabreakdown → 2009 ·New England Journal of Medicine ·Gemma G. Kenter,Marij J.P. Welters,A. Rob P.M. Valentijn,Margriet J. Löwik,Dorien M. A. Berends-van der Meer,Annelies P.G. Vloon,(unknown),Lorraine M. Fathers,Rienk Offringa,Jan W. Drijfhout,Amon R. Wafelman,Jaap Oostendorp,Gert Jan Fleuren,Sjoerd H. van der Burg,Cornelis J.M. Melief	803
13	Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial 2009 ·International Journal of Cancer ·Ninke Leffers,Annechien J.A. Lambeck,Marloes J.M. Gooden,Baukje‐Nynke Hoogeboom,Rinze Wolf,(unknown),Bouke G. Hepkema,Pax H.B. Willemse,Barbara H. W. Molmans,Harry Hollema,Jan W. Drijfhout,Willem Sluiter,A. Rob P.M. Valentijn,(unknown),Jaap Oostendorp,Ate G.J. van der Zee,Cornelis J.M. Melief,Sjoerd H. van der Burg,Toos Daemen,Hans W. Nijman	109
14	Robust T-cell responses and clinical responses following long peptide vaccination against high risk HPV-16 2008 ·Cornelis J.M. Melief,Marij J.P. Welters,Margriet J. Löwik,Annelies P.G. Vloon,Jan W. Drijfhout,A. Rob P.M. Valentijn,Amon R. Wafelman,Gert Jan Fleuren,Rienk Offringa,Sjoerd H. van der Burg,Gemma G. Kenter	1
15	Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasia 2008 ·International Journal of Cancer ·Muriel van den Hende,Mariëtte I.E. van Poelgeest,Jeanette M. van der Hulst,Joan de Jong,Jan W. Drijfhout,Gert Jan Fleuren,A. Rob P.M. Valentijn,Amon R. Wafelman,(unknown),Cornelis J.M. Melief,Rienk Offringa,Sjoerd H. van der Burg,Gemma G. Kenter	34
16	Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model 2004 ·Vaccine ·Marij J.P. Welters,Dmitri V. Filippov,Susan J. F. van den Eeden,Kees L. M. C. Franken,Jan Nouta,A. Rob P.M. Valentijn,Gijs A. van der Marel,Herman S. Overkleeft,Grayson B. Lipford,Rienk Offringa,Cornelis J.M. Melief,Jacques H. van Boom,Sjoerd H. van der Burg,Jan W. Drijfhout	15
17	Inhibition of human smooth muscle cell proliferation in culture by farnesyl pyrophosphate analogues, inhibitors of in vitro protein:farnesyl transferase 1999 ·Biochemical Pharmacology ·Louis Cohen,Elsbet Pieterman,Rick E.W. van Leeuwen,Junrong Du,Pascale Nègre‐Aminou,A. Rob P.M. Valentijn,Mark Overhand,Gijs A. van der Marel,Jacques H. van Boom	16
18	The survival and growth of acid-adapted mesophilic pathogens that contaminate meat after lactic acid decontamination 1998 ·Journal of Applied Microbiology ·P. van Netten,A. Rob P.M. Valentijn,D. À. A. Mossel,(unknown)	19
19	Synthesis of Clustered Disaccharide Polyphosphate Analogues of Adenophostin A 1997 ·Tetrahedron Letters ·Martin de Kort,A. Rob P.M. Valentijn,Gijs A. van der Marel,Jacques H. van Boom	16
20	Different analogues of farnesyl pyrophosphate inhibit squalene synthase and protein: Farnesyltransferase to different extents 1995 ·Biochemical Pharmacology ·Louis Cohen,A. Rob P.M. Valentijn,(unknown),Rick E.W. van Leeuwen,Rik Huisman,Robert J. Lutz,Gijs A. van der Marel,Jacques H. van Boom	26

About A. Rob P.M. Valentijn

A. Rob P.M. Valentijn is a scholar working on Microbiology, Immunology and Organic Chemistry, having authored 55 papers that have together received 3.2k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (17 papers), Cervical Cancer and HPV Research (11 papers) and Carbohydrate Chemistry and Synthesis (9 papers). The work is most often cited by research in Immunology (1.9k citations), Oncology (1.2k citations) and Epidemiology (775 citations). A. Rob P.M. Valentijn has collaborated with scholars based in Netherlands, United States and Czechia. Frequent co-authors include Sjoerd H. van der Burg, Jaap Oostendorp, Marij J.P. Welters, Cornelis J.M. Melief, Jan W. Drijfhout, Gemma G. Kenter, Gert Jan Fleuren, Dorien M. A. Berends-van der Meer, Annelies P.G. Vloon and Rienk Offringa. Their work appears in journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Angewandte Chemie International Edition.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact